Time to initial review by oncology clinical pathways committees for new FDA approvals/ label expansions

被引：0
|
作者：
Caranfa, Christine L.
Addonizio, Joanna
Desravines, Belinda
Rezaee, Daniel
Waid, Omar
Hamilton, Joanna M.
Selesnick, Victoria H.
Scalzo, Michael
Jackman, David Michael
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13523
引用
收藏
页数：1
相关论文
共 50 条
  • [31] An FDA analysis of clinical hold deficiencies affecting investigational new drug applications for oncology products
    Manning, Michael L.
    Thompson, Matthew D.
    Saber, Haleh
    Maher, Virginia E.
    Crich, Joyce Z.
    Leighton, John K.
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2020, 110
  • [32] IMPACT OF FDA EXPEDITED REVIEW PROGRAMS ON NEW DRUG APPROVAL TIME
    Ronnebaum, S.
    Smith, D.
    Andrawes, M.
    VALUE IN HEALTH, 2024, 27 (06) : S7 - S7
  • [33] American Society for Clinical Oncology objects to proposed regulation of stem cell transplantation; Urges expedited approvals; Applauds payment for off-label uses
    不详
    BIOTECHNOLOGY LAW REPORT, 1997, 16 (03): : 348 - 350
  • [34] The Use of Risperidone in Behavioral and Psychological Symptoms of Dementia: A Review of Pharmacology, Clinical Evidence, Regulatory Approvals, and Off-Label Use
    Yunusa, Ismaeel
    El Helou, Marie Line
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [35] Scientific Review Committees as part of institutional review of human participant research: Initial implementation at institutions with Clinical and Translational Science Awards
    Selker, Harry P.
    Welch, Lisa C.
    Patchen-Fowler, Elizabeth
    Breeze, Janis L.
    Terrin, Norma
    Parajulee, Anshu
    LeClair, Amy
    Naeim, Arash
    Marnocha, Rebecca
    Morelli Novak, Julie
    Caldwell, Christine Sego
    Cola, Philip A.
    Croker, Jennifer A.
    Cifu, David X.
    Williams, Kirsten M.
    Snyder, Denise C.
    Kitterman, Darlene
    JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 4 (02) : 115 - 124
  • [36] ANALYSIS OF FORTY-ONE YEARS OF US FOOD AND DRUG ADMINISTRATION APPROVALS, REGULATORY PATHWAYS, AND REVIEW TIME OF NEW DRUGS AND BIOLOGICS: A RETROSPECTIVE COHORT STUDY
    Seoane-Vazquez, E.
    Rodriguez-Monguio, R.
    Powers, J. H.
    VALUE IN HEALTH, 2024, 27 (06) : S217 - S217
  • [37] Time intervals between US Food and Drug Administration (FDA) and European Medicines Agency (EMA) new cancer therapy approvals.
    Lythgoe, Mark
    Krell, Jonathan
    Warner, Jeremy Lyle
    Desai, Aakash
    Khaki, Ali Raza
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980–2022
    Enrique Seoane-Vazquez
    Rosa Rodriguez-Monguio
    John H. Powers
    Scientific Reports, 14
  • [39] ONCOLOGY NURSE NAVIGATORS: TAKING CHARGE AND FORGING NEW PATHWAYS TO REDUCE TIME TO TREATMENT
    Mulholland, Jennifer
    Barrett, Katherine
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [40] Lessons from clinical trials in surgical oncology: Time for a new paradigm?
    van de Velde, CJH
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S299 - S299
12345